Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MKK-RHP12
- Development stage
- Preclinical
- Lead developer
- MAXVAX Biotechnology
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
MKK-RHP12 is a 12-valent recombinant human papillomavirus (HPV) vaccine candidate currently under development by MAXVAX Biotechnology. The vaccine is engineered using recombinant protein technology to produce virus-like particles (VLPs) that mimic the structure of twelve different HPV serotypes. By targeting a broader range of HPV types than existing 4-valent or 9-valent vaccines, MKK-RHP12 aims to provide expanded protection against high-risk strains associated with cervical, vulvar, vaginal, and anal cancers, as well as low-risk strains responsible for genital warts. The project is currently in the preclinical stage, utilizing the company's proprietary adjuvant platforms to optimize the immune response and ensure long-term efficacy.
- Other names
- 12-valent Recombinant HPV Vaccine12-valent Recombinant Human Papillomavirus Vaccine
Beyond the preview
Go deeper on MKK-RHP12.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MKK-RHP12.